BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 1417014)

  • 1. [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].
    Ariyoshi Y; Ota K; Taguchi T; Furue H; Niitani H; Tsukagoshi S; Ikeda M; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2057-70. PubMed ID: 1417014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].
    Ohta J; Taguchi T; Furue H; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2041-55. PubMed ID: 1417013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis].
    Akasaka Y; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1359-74. PubMed ID: 1386977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1347-57. PubMed ID: 1386976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin].
    Suminaga M; Furue H; Taguchi T; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1879-90. PubMed ID: 1387774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
    Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1891-903. PubMed ID: 1387775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
    Hardy J; Daly S; McQuade B; Albertsson M; Chimontsi-Kypriou V; Stathopoulos P; Curtis P
    Support Care Cancer; 2002 Apr; 10(3):231-6. PubMed ID: 11904788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
    Nukariya N; Niitani H; Taguchi T; Furue H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Ohta J
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1375-85. PubMed ID: 1386978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2071-84. PubMed ID: 1417015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in gynecological cancer patients on cisplatin].
    Eguchi F; Taguchi T; Furue H; Ikeda M; Tsukakoshi S;
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1423-9. PubMed ID: 11681251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
    Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of ondansetron hydrochloride injection and tablet against nausea and vomiting in lung cancer patients receiving carboplatin].
    Miyamoto Y; Yagi K; Teramachi M; Oomasa M; Tomiyama K
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):125-30. PubMed ID: 9987508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
    Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
    J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.